• Modelling the Effect of Short-Course Multidrug-Resistant Tuberculosis Treatment in Karakalpakstan, Uzbekistan

      Trauer, JM; Achar, J; Parpieva, N; Khamraev, A; Denholm, JT; Falzon, D; Jaramillo, E; Mesic, A; du Cros, P; McBryde, ES (BioMed Central, 2016-11-18)
      Multidrug-resistant tuberculosis (MDR-TB) is a major threat to global TB control. MDR-TB treatment regimens typically have a high pill burden, last 20 months or more and often lead to unsatisfactory outcomes. A 9-11 month regimen with seven antibiotics has shown high success rates among selected MDR-TB patients in different settings and is conditionally recommended by the World Health Organization.